Pharmafile Logo

News and Press Releases

Samsung Bioepis Presents Nonclinical Data for its First Novel Antibody-Drug Conjugate Candidate SBE303 at AACR 2026  

Nonclinical findings from pharmacology, pharmacokinetics, and toxicology studies support the advancement of SBE303 into clinical development with a favorable therapeutic index (TI), with its first-in-human Phase I clinical trial began...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: April 20, 2026

Samsung Bioepis
76, Songdogyoyuk-ro, Yeonsu-gu, Incheon

Freya Biosciences announces positive Phase 1 first-in-human data with FB301 for IVF-related embryo implantation failure

FB301 was safe and well tolerated in healthy female subjects, with all primary and secondary endpoints met Clinically meaningful microbiome modulation observed, including significant improvement up to 6-month follow-up Results...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: April 16, 2026

Freya Biosciences
info@freyabiosciences.com
Fruebjergvej 3, 2100 Copenhagen, Denmark

STORM Therapeutics Secures $56 Million Series C Financing and Doses First Patient in Phase 2 Sarcoma Trial of STC‑15

The proceeds will support the advancement of STC-15 in a Phase 2 study in select sarcoma indications First‑in‑class METTL3 inhibitor reprograms malignant progenitor cells by modulating mRNA methylation 16 April...

Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: April 16, 2026

Storm Therapeutics
info@stormtherapeutics.com
Babraham Hall House, Babraham, Cambridge CB22 3AT

Kainova Therapeutics Expands Phase I/II Trial of DT-7012, a Treg-depleting Anti-CCR8 Antibody, with First Patient Dosed in Europe

First patient dosed in France, expanding the DOMISOL study beyond Australia DT 7012 is being evaluated as monotherapy and in combination with pembrolizumab in a global clinical development program. 9...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: April 9, 2026

Kainova Therapeutics
contact@kainovatx.com
7171 Frederick Banting Montreal, QC H4S 1Z9 Canada

ESCMID Global 2026: Shionogi presents new real-world data highlighting clinical effectiveness of Fetroja/Fetcroja (cefiderocol) in MBL-producing Enterobacterales infections

Real world evidence study carried out in Spain demonstrates 68% clinical cure rate at day 14, and 83% overall survival at day 28, for patients infected with highly resistant metallo-beta...

Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: April 7, 2026

SHIONOGI
contact@shionogi.eu
33 Kingsway, London, WC2B 6UF, UK

Levicept Announces The Lancet Publication of LEVI-04 Phase II Clinical Trial Results, Showing Significant Reduction in Pain and Symptoms of Osteoarthritis

Significant improvements in pain, function and patient global outcomes demonstrated LEVI-04 well tolerated and exhibits a favourable safety profile. 30 March 2026 -- Sandwich, UK -- Levicept Ltd, a biotechnology...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: March 30, 2026

Levicept
info@levicept.com
Innovation House Discovery Park Ramsgate Road Sandwich Kent CT13 9ND

Tozorakimab met primary endpoint in both OBERON and TITANIA Phase III trials in patients with COPD

First-ever IL-33-targeting biologic to demonstrate statistically significant and highly clinically meaningful reductions in COPD exacerbations in two replicate Phase III clinical trials 27 March 2026 -- Cambridge, UK -- Positive...

Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: March 27, 2026

AstraZeneca
Medical.InformationUK@astrazeneca.com
PLC 1 Francis Crick Avenue Cambridge Biomedical Campus Cambridge CB2 0AA UK

ADOA PROGRAM – PRESENTATION AT NANOS 2026

PYC is a precision medicine company dedicated to changing the lives of patients with genetic diseases who have no treatment options available One of PYC’s clinical-stage programs is an investigational...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: March 24, 2026

PYC Therapeutics
info@pyctx.com
6 Verdun Street, Nedlands, Western Australia 6009

Tilray Medical Announces Major Expansion of Medical Cannabis Portfolio in Australia

19 March 2026 -- New York, US and Sydney, Australia -- Tilray Medical, a recognized global leader in medical cannabis and a division of Tilray Brands, Inc. today announced its...

Category: Biotechnology, Drug Discovery, Other, Pharmaceutical
Posted: March 19, 2026

Tilray Medical
info@tilraymedical.com

Kainova Therapeutics Announces Positive Phase I Results for DT-9081, an Oral EP4 Receptor Antagonist, in Advanced Solid Tumors

Phase I results demonstrate favorable safety, sustained target engagement, and early signs of anti-tumor activity Reinforce EP4 receptor antagonism as a validated, high-value strategy to overcome immunotherapy resistance. 10 March...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: March 10, 2026

Kainova Therapeutics
contact@kainovatx.com
7171 Frederick Banting Montreal, QC H4S 1Z9 Canada

European Commission approves AKEEGA (niraparib and abiraterone acetate dual action tablet) for the treatment of patients with BRCA1/2-mutated metastatic hormone-sensitive prostate cancer (mHSPC)

Niraparib and abiraterone acetate regimen demonstrates clinically meaningful delay in disease progression, nearly halving the risk of progression or death, with an early trend toward improved overall survival versus standard...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: March 9, 2026

Johnson & Johnson Innovative Medicine
mediaenquiries@its.jnj.com
Janssen-Cilag Limited 50-100 Holmers Farm Way High Wycombe Buckinghamshire HP12 4EG

Curium Announces Pharmacokinetics and Dosimetry Data for Investigational Lutetium-177 Zadavotide Guraxetan in Metastatic Castration-Resistant Prostate Cancer at ASCO GU 2026

Dosimetry data from the Phase 3 ECLIPSE substudy demonstrated favorable organ radiation absorbed doses supporting administration of 7.4 GBq for up to six cycles 26 February 2026 -- Massachusetts, US...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: March 3, 2026

Curium Pharma
contactus@curiumpharma.com
Perceptive 55 Blue Sky Drive Burlington Massachusetts 01803 United States

SolasCure completes phase II clinical trial, demonstrating accelerated healing with Aurase Wound Gel

Aurase Wound Gel shows 22x faster debridement and 7x faster healing compared to standard of care in sloughy venous leg ulcers, supporting advancement to the next phase of development Data...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: February 24, 2026

SolasCure
wellington house East Rd, Petersfield, Cambridge CB1 1BH

Oncoinvent to Present Positive 24-month Follow-up Data from Phase 1 Ovarian Cancer Study of Radspherin at ESGO 2026

9 of 10 patients at the highest dose remained free from peritoneal recurrence at 24 months at the recommended dose 17 February 2026 -- Oslo, Norway -- Oncoinvent, a biotech...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: February 17, 2026

Oncoinvent
oncoinvent@oncoinvent.com
Gullhaugveien 7 0484 Oslo Norway

FundaMental Pharma to showcase groundbreaking approach to treatment-resistant depression at Bio-Neuroscience Conference

Presentation will highlight lead clinical candidate FMP374, a novel dual-acting NMDAR modulator advancing toward IND-enabling studies for TRD 17 February 2026 -- Heidelberg, Germany -- FundaMental Pharma GmbH, a preclinical-stage...

Category: Biotechnology, Drug Discovery, Other, Pharmaceutical
Posted: February 17, 2026

FundaMental Pharma
info@fundamentalpharma.com
Nikola-Tesla-Straße 1 D-69124 Heidelberg / Germany